Take a look at the two prescription strengths of BREO
When choosing the starting dosage strength of BREO, consider patients’ disease severity, based on their previous asthma therapy, including the ICS dosage, as well as patients’ current control of asthma symptoms and risk of future exacerbation.
- The recommended starting dose is BREO 100/25 administered as 1 inhalation once daily.
- For patients who do not respond adequately to BREO 100/25, increasing the dose to BREO 200/25 may provide additional improvement in asthma control.
- The maximum recommended dosage of BREO is 1 inhalation of BREO 200/25 once daily.
The median time to onset, defined as a 100-mL increase from baseline in mean forced expiratory volume in 1 second (FEV1), was approximately 15 minutes after beginning treatment. Individual patients will experience a variable time to onset and degree of symptom relief.
BREO is delivered in a disposable light gray and pale blue plastic inhaler containing 2 foil blister strips of powder, and it is intended for oral inhalation only. One strip contains fluticasone furoate (100 or 200 mcg per blister), and the other strip contains vilanterol (25 mcg per blister).
- Bernstein DI, Bateman ED, Woodcock A, et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2018;55(8):890-897.
- Bleecker ER, Lötvall J, O’Byrne PM, et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014;2(5):553-561.
- Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312-319.
- Data on file, GSK.
- O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43:773-782.
- Kerwin E, Barnes N, Gibbs M, et al. Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials. J Asthma. 2018;55(8):890-897.
- Data on file, GSK. Study 201594.